Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Ven­tyx Bio­sciences has axed the de­vel­op­ment of its ex­per­i­men­tal pso­ri­a­sis drug af­ter lack­lus­ter Phase II re­sults, send­ing its stock plum­met­ing about 73% to $3.75 in pre­mar­ket trad­ing on Tues­day.

Its oral ty­ro­sine ki­nase 2 in­hibitor, VTX958, hit the pri­ma­ry and sec­ondary end­points of the tri­al — but did not show enough ef­fi­ca­cy to sup­port de­vel­op­ment, Ven­tyx CEO Ra­ju Mo­han said in a Mon­day state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER